Amneal to Report Fourth Quarter and Full Year 2025 Results on February 27, 2026
Rhea-AI Summary
Amneal (NASDAQ: AMRX) will report its fourth quarter and full year 2025 financial results on Friday, February 27, 2026, before market open. The company will host an audio webcast at 8:30 a.m. ET and post results and the live webcast via the Investor Relations website.
Investors can register for the webcast on the company IR site or join by conference line at 1 (833) 470-1428 (U.S.) using access code 937407; international toll-free numbers and a replay will be posted after the call.
Positive
- None.
Negative
- None.
News Market Reaction – AMRX
In the Jan 27 session, AMRX gained 1.92%, reflecting a mild positive market reaction. Our momentum scanner triggered 6 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jan 09 | R&D collaboration | Positive | -1.8% | Collaboration and option deal for KFRX06 Parkinson’s candidate pre-IND development. |
| Dec 22 | FDA approval | Positive | +0.2% | FDA approvals of two denosumab biosimilars referencing Prolia and XGEVA. |
| Dec 09 | FDA approval | Positive | +2.0% | FDA approval of epinephrine injection vials for institutional hospital use. |
| Dec 05 | Clinical data | Positive | +2.4% | Positive interim Phase 4 CREXONT data improving Good On time and symptoms. |
| Dec 02 | Investor conferences | Neutral | -2.5% | Participation in upcoming investor conferences with webcast presentations. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent company-specific news has mostly seen price moves align with positive catalysts, with one notable divergence on collaboration news.
Over the past few months, AMRX reported multiple positives, including FDA approvals for denosumab biosimilars and an epinephrine injection, as well as positive Phase 4 ELEVATE-PD results for CREXONT. These events often coincided with modest positive price reactions. An earlier research collaboration on a Parkinson’s candidate saw a negative move despite constructive terms. Today’s earnings date announcement fits into a period of expanding product approvals and pipeline activity heading into reported 2025 results.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BRIDGEWATER, N.J., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal” or the “Company”), today announced that the Company will release its fourth quarter and full year 2025 financial results on Friday, February 27, 2026, prior to market open. The Company will host an audio webcast at 8:30 a.m. ET.
The financial results and live webcast will be accessible through the Investor Relations section of the Company's website at https://investors.amneal.com. Individuals may register for the webcast by clicking the link here. To access the call through a conference line, dial 1 (833) 470-1428 (in the U.S.) or for a list of toll-free international numbers, visit this here. The access code for the call is 937407. A replay of the conference call will be posted shortly after the call.
About Amneal
Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX), headquartered in Bridgewater, NJ, is a global biopharmaceutical company. We make healthy possible through the development, manufacturing, and distribution of a diverse portfolio of over 290 pharmaceuticals, primarily within the United States. In its Affordable Medicines segment, the Company is expanding across a broad range of complex product categories and therapeutic areas, including injectables and biosimilars. In its Specialty segment, Amneal has a growing portfolio of branded pharmaceuticals focused primarily on central nervous system and endocrine disorders. Through its AvKARE segment, the Company is a distributor of pharmaceuticals and other products for the U.S. federal government, retail, and institutional markets. For more information, please visit www.amneal.com and follow us on LinkedIn.
Investor Contact
Anthony DiMeo
VP, Investor Relations
anthony.dimeo@amneal.com
